Literature DB >> 8098724

Transfected Leishmania expressing biologically active IFN-gamma.

J F Tobin1, S L Reiner, F Hatam, S Zheng, C L Leptak, D F Wirth, R M Locksley.   

Abstract

Infection of susceptible BALB/c mice with Leishmania major leads to progressive infection with the failure to expand and activate Th1 CD4+ T cells that elaborate IFN-gamma, a critically implicated cytokine for control of disease. We used the recently described capacity to express foreign genes in trypanosomatids to introduce into Leishmania the murine IFN-gamma gene on a drug-selectable plasmid under the constitutive control of intergenic tubulin sequences. Several clones of L. major were established and demonstrated to contain IFN-gamma DNA and IFN-gamma RNA that was appropriately trans-spliced with the Leishmania-specific leader sequence, and to secrete IFN-gamma into the media. The secreted IFN-gamma was biologically active as assessed by up-regulation of class II MHC Ag and induction of macrophage nitric oxide synthase activity in a macrophage cell line. Infection of nude mice with IFN-gamma-containing organisms resulted in significantly slower progression of disease as compared to infection with organisms containing the empty plasmid, suggesting that biologically important activation of infected macrophages might be occurring in vivo. Infection of genetically susceptible BALB/c mice, however, did not impede the expansion of Th2 cells and the inexorable progression of disease. Despite the demonstration of increased levels of IFN-gamma transcription in vivo, induction of nitric oxide synthase in macrophages and expression of Ly-6, and IFN-gamma-inducible Ag, on CD4+ lymphocytes could not be shown. In all cases, organisms recovered from tissue amastigotes contained the IFN-gamma plasmid and secreted active IFN-gamma. The data confirm earlier studies that IFN-gamma alone is not sufficient to impede activation and maturation of Th2 cells in susceptible mice, even when targeted directly to the infected cell.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098724

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

2.  Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection.

Authors:  Mustapha Chamekh; Vincent Vercruysse; Mohammed Habib; Maxime Lorent; Michel Goldman; Abdelmounaïm Allaoui; Bernard Vray
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Reduced pathology following infection with transgenic Leishmania major expressing murine CD40 ligand.

Authors:  Ann E Field; Sagie Wagage; Sean M Conrad; David M Mosser
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

4.  Development of a safe live Leishmania vaccine line by gene replacement.

Authors:  R G Titus; F J Gueiros-Filho; L A de Freitas; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

5.  The expression of biologically active human p53 in Leishmania cells: a novel eukaryotic system to produce recombinant proteins.

Authors:  W W Zhang; H Charest; G Matlashewski
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

6.  Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Authors:  Carole Dumas; Anthony Muyombwe; Gaétan Roy; Claudine Matte; Marc Ouellette; Martin Olivier; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

7.  Transfected Plasmodium knowlesi produces bioactive host gamma interferon: a new perspective for modulating immune responses to malaria parasites.

Authors:  Hastings Ozwara; Jan A M Langermans; Clemens H M Kocken; Annemarie van der Wel; Peter H van der Meide; Richard A W Vervenne; Jason M Mwenda; Alan W Thomas
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 8.  Transgenic Leishmania and the immune response to infection.

Authors:  L Beattie; K J Evans; P M Kaye; D F Smith
Journal:  Parasite Immunol       Date:  2008-02-04       Impact factor: 2.280

9.  Cloning and Expression of Leishmania infantum LPG3 Gene by the Lizard Leishmania Expression System.

Authors:  Leila Pirdel; Ahmad Zavaran Hosseini; Bahram Kazemi; Manoochehr Rasouli; Mojgan Bandehpour; Sara Soudi
Journal:  Avicenna J Med Biotechnol       Date:  2012-10

10.  T cell and non-T cell compartments can independently determine resistance to Leishmania major.

Authors:  A H Shankar; R G Titus
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.